Personalized medicine is rapidly coming of age. Drug development pipelines are full of targeted therapies that offer hope of effective new treatment options for patients. In fact, the Personalized Medicine Coalition’s recent Personalized Medicine at FDA: 2016 Progress Report illustrates that, for the third year in a row, personalized medicines accounted for more than 20 percent of the new molecular entities approved by the FDA, a trend PMC says reflects the pharmaceutical industry’s commitment to investing in the space.
Despite this commitment and the significant progress made to date, the sector still faces scientific, regulatory, and reimbursement barriers as well as challenges regarding clinical adoption in its efforts to get targeted therapies through development and to patients. This panel will discuss specifically how pharma and other key stakeholders are addressing the challenge of adopting biomarkers from the preclinical to the clinical stage:
Nicholas C. Dracopoli, PhD, Vice President and Head of Oncology Biomarkers, Janssen Research & Development, LLC
Gregory Frank, PhD, Former Director, Business Development, 23andMe
Maurie Markman, MD, President of Medicine and Science, Cancer Treatment Centers of America
MODERATOR: Kalidip “KC” Choudhury, PhD, Vice President. Business Development, XBiotech